# Hrain Biotechnology Co., Ltd.: Observational study in B-Cell Non-Hodgkin Lymphoma (NHL) (200 participants)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Hrain Biotechnology Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
| NCT ID | NCT07888530 |
| Phase | Observational |
| Status | not yet recruiting |
| Conditions | B-Cell Non-Hodgkin Lymphoma (NHL) |
| Intervention types | drug |
| Target enrollment | 200 |
| Posted | 2026-10-22 |
| Planned start | 2026-10-30 |
| Event | Newly registered study |
| Event date | 2026-10-22 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 200 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07888530). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.